

Biotechnology Fund
SCHEDULE OF INVESTMENTS (Unaudited)

December 31, 2021

	Shares	Value
COMMON STOCKS[†] - 99.3%		
Biotechnology - 70.8%		
Amgen, Inc.	38,551	\$ 8,672,819
Moderna, Inc.*	29,613	7,521,110
Gilead Sciences, Inc.	102,593	7,449,278
Regeneron Pharmaceuticals, Inc.*	10,245	6,469,922
Vertex Pharmaceuticals, Inc.*	27,017	5,932,933
Illumina, Inc.*	15,460	5,881,602
Corteva, Inc.	98,408	4,652,730
Biogen, Inc.*	19,255	4,619,660
Seagen, Inc.*	26,829	4,147,763
Royalty Pharma plc — Class A	99,744	3,974,798
BioNTech SE ADR ^{*,1}	15,418	3,974,761
Horizon Therapeutics plc*	36,104	3,890,567
Alnylam Pharmaceuticals, Inc.*	19,828	3,362,432
BioMarin Pharmaceutical, Inc.*	36,440	3,219,474
Incyte Corp.*	42,795	3,141,153
United Therapeutics Corp.*	12,013	2,595,769
Guardant Health, Inc.*	25,001	2,500,600
Biohaven Pharmaceutical Holding Company Ltd.*	17,706	2,440,064
CRISPR Therapeutics AG ^{*,1}	30,949	2,345,315
Mirati Therapeutics, Inc.*	15,595	2,287,631
Novavax, Inc.*	15,690	2,244,768
Arrowhead Pharmaceuticals, Inc.*	30,464	2,019,763
Blueprint Medicines Corp.*	18,291	1,959,149
Arena Pharmaceuticals, Inc.*	20,183	1,875,808
Ultragenyx Pharmaceutical, Inc.*	22,258	1,871,675
Exelixis, Inc.*	102,380	1,871,506
Halozyne Therapeutics, Inc.*	46,455	1,867,956
Fate Therapeutics, Inc.*	31,339	1,833,645
Denali Therapeutics, Inc.*	40,295	1,797,157
Beam Therapeutics, Inc.*	21,897	1,744,972
Apellis Pharmaceuticals, Inc.*	35,980	1,701,135
NeoGenomics, Inc.*	47,780	1,630,254
Ionis Pharmaceuticals, Inc.*	52,484	1,597,088
Twist Bioscience Corp.*	18,149	1,404,551
Iovance Biotherapeutics, Inc.*	70,652	1,348,747
TG Therapeutics, Inc.*	70,397	1,337,543
Veracyte, Inc.*	31,551	1,299,901
BioCryst Pharmaceuticals, Inc.*	93,779	1,298,839
ChemoCentryx, Inc.*	35,140	1,279,447
Emergent BioSolutions, Inc.*	27,123	1,179,037
Cassava Sciences, Inc. ^{*,1}	23,842	1,041,896
Editas Medicine, Inc.*	37,102	985,058
Bridgebio Pharma, Inc. ^{*,1}	48,305	805,727
Total Biotechnology		125,076,003
Pharmaceuticals - 16.9%		
AbbVie, Inc.	90,728	12,284,571
AstraZeneca plc ADR	66,425	3,869,256
Viatris, Inc.	239,216	3,236,593
Jazz Pharmaceuticals plc*	21,490	2,737,826
Intellia Therapeutics, Inc.*	18,875	2,231,780
Neurocrine Biosciences, Inc.*	25,982	2,212,887
Sarepta Therapeutics, Inc.*	24,541	2,209,917
Ironwood Pharmaceuticals, Inc. — Class A*	92,609	1,079,821
Total Pharmaceuticals		29,862,651
Healthcare-Products - 6.4%		
Bio-Techne Corp.	7,001	3,621,897
Exact Sciences Corp.*	35,370	2,752,847
Natera, Inc.*	24,363	2,275,261
Pacific Biosciences of California, Inc.*	76,186	1,558,765
CareDx, Inc.*	26,000	1,182,480
Total Healthcare-Products		11,391,250
Healthcare-Services - 5.2%		
ICON plc*	9,725	3,011,833
Syneos Health, Inc.*	25,019	2,568,951
Medpace Holdings, Inc.*	10,080	2,193,811
Invitae Corp.*	89,800	1,371,246
Total Healthcare-Services		9,145,841
Total Common Stocks (Cost \$95,501,594)		175,475,745
	Face Amount	
REPURCHASE AGREEMENTS^{††,2} - 0.7%		
J.P. Morgan Securities LLC issued 12/31/21 at 0.05% due 01/03/22	\$ 681,359	681,359
Barclays Capital, Inc. issued 12/31/21 at 0.01% due 01/03/22	281,790	281,790
BofA Securities, Inc. issued 12/31/21 at 0.02% due 01/03/22	256,173	256,173
Total Repurchase Agreements (Cost \$1,219,322)		1,219,322
	Shares	
SECURITIES LENDING COLLATERAL^{†,3} - 3.5%		
Money Market Fund		
First American Government Obligations Fund — Class Z, 0.02% ⁴	6,174,645	6,174,645
Total Securities Lending Collateral (Cost \$6,174,645)		6,174,645
Total Investments - 103.5% (Cost \$102,895,561)	\$	182,869,712
Other Assets & Liabilities, net - (3.5)%		(6,172,807)
Total Net Assets - 100.0%	\$	176,696,905

* Non-income producing security.

[†] Value determined based on Level 1 inputs.

^{††} Value determined based on Level 2 inputs.

¹ All or a portion of this security is on loan at December 31, 2021.

² Repurchase Agreements.

³ Securities lending collateral.

⁴ Rate indicated is the 7-day yield as of December 31, 2021.

ADR — American Depositary Receipt
plc — Public Limited Company